Matthew Coghlan

Matthew Coghlan has a PhD in Biochemistry from the University of Cambridge and was a Royal Society NATO Post-Doctoral Fellow at Harvard Medical School. Subsequently, Matthew has gained 25 years of experience in Pharmaceutical R&D in Metabolic Disease across several global Pharma companies in Europe and the US. Since joining Eli Lilly and Company in 2018 Matthew has provided strategic leadership of the incretin portfolio that includes peptide and small molecule programs from early Research through the end of Phase 2. Further, Matthew has overseen an extensive program of pre-clinical research in support of the Lilly Incretin R&D Portfolio. This highly collaborative research continues to yield new insights into the mechanisms of action of tirzepatide, retatrutide and orforglipron. In his current Data Science role, Matthew leads efforts to leverage human data to inform R&D portfolios across Lilly.